Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)



Status:Archived
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:June 2010
End Date:April 2012

Use our guide to learn which trials are right for you!

A Pilot Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)


A Study of Bafetinib as Treatment for Patients with Relapsed or Refractory B-Cell Chronic
Lymphocytic Leukemia (B-CLL).


Bafetinib is a dual protein kinase inhibitor, targeting both bcr/abl and Lyn kinases. B-cell
chronic lymphocytic leukemia cells overexpress Lyn kinase compared to normal B lymphocytes
as well as acute leukemias (ALL and AML), and inhibition of Lyn kinase induces apoptosis in
cultures of B-CLL cells. Thus, bafetinib may stop the growth of B-CLL cells by inhibiting
Lyn kinase, the molecule that couples the B cell receptor to downstream signaling.


We found this trial at
3
sites
Duarte, California 91010
5
mi
from 91732
Duarte, CA
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
100 NE Loop 410; Suite 600
San Antonio, Texas 78216
210-424-1600
Cancer Care Centers of South Texas At Cancer Care Centers of South Texas, we are...
1182
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials